These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 1553167)

  • 1. Factors influencing serum CA 125 levels in normal women.
    Grover S; Quinn MA; Weideman P; Koh H
    Obstet Gynecol; 1992 Apr; 79(4):511-4. PubMed ID: 1553167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA 125 levels in menopausal women.
    Westhoff C; Gollub E; Patel J; Rivera H; Bast R
    Obstet Gynecol; 1990 Sep; 76(3 Pt 1):428-31. PubMed ID: 2381621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
    Jacobs IJ; Oram DH; Bast RC
    Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sources of variability in normal CA 125 levels.
    Westhoff C; Levin B; Ladd G; O'Connor J
    Cancer Epidemiol Biomarkers Prev; 1992; 1(5):357-9. PubMed ID: 1305467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer.
    Einhorn N; Sjövall K; Knapp RC; Hall P; Scully RE; Bast RC; Zurawski VR
    Obstet Gynecol; 1992 Jul; 80(1):14-8. PubMed ID: 1603484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
    Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis.
    Makar AP; Kristensen GB; Kaern J; Børmer OP; Abeler VM; Tropé CG
    Obstet Gynecol; 1992 Jun; 79(6):1002-10. PubMed ID: 1579296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
    Cane P; Azen C; Lopez E; Platt LD; Karlan BY
    Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of hormone replacement therapy on antithrombin III and protein C levels in menopausal women.
    Lacroix KA; Bean C; Reilly R; Curran-Celentano J
    Clin Lab Sci; 1997; 10(3):145-8. PubMed ID: 10167774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum CA-125 measurements > 65 U/mL. Clinical value.
    Eltabbakh GH; Belinson JL; Kennedy AW; Gupta M; Webster K; Blumenson LE
    J Reprod Med; 1997 Oct; 42(10):617-24. PubMed ID: 9350014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
    Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
    Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center.
    Muto MG; Cramer DW; Brown DL; Welch WR; Harlow BL; Xu H; Brucks JP; Tsao SW; Berkowitz RS
    Gynecol Oncol; 1993 Oct; 51(1):12-20. PubMed ID: 8244166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A study of preclinical and clinical usefulness of new tumor markers of ovarian carcinoma, CA 54/61 and CA 602. 1. Evaluation of the diagnostic accuracy of CA 54/61, a study of the normal range of its values and its correlation with other tumor markers].
    Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hasimoto M
    Gan To Kagaku Ryoho; 1992 Jun; 19(6):827-35. PubMed ID: 1605661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of ovarian cancer: a survey of the practice of prophylactic oophorectomy by consultant gynaecologists in Ireland.
    Geary M; Geoghegan A; Foley M
    Ir Med J; 1997; 90(5):186-7. PubMed ID: 9345830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Menopause, but not age, is an independent risk factor for fasting plasma glucose levels in nondiabetic women.
    Otsuki M; Kasayama S; Morita S; Asanuma N; Saito H; Mukai M; Koga M
    Menopause; 2007; 14(3 Pt 1):404-7. PubMed ID: 17213751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen replacement therapy following oophorectomy in women with a family history of ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Aiduk C
    Gynecol Oncol; 1997 Jul; 66(1):103-7. PubMed ID: 9234929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer.
    Lowery AJ; Sweeney KJ; Molloy AP; Hennessy E; Curran C; Kerin MJ
    BMC Cancer; 2008 Sep; 8():279. PubMed ID: 18826631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer.
    Zurawski VR; Broderick SF; Pickens P; Knapp RC; Bast RC
    Obstet Gynecol; 1987 Apr; 69(4):606-11. PubMed ID: 2434895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.